Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for Severe Right Heart Failure Due to Pulmonary Hypertension
jRCT2051220042Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of nitric oxide in pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH) and Right heart dysfunction (RHF) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Change in pulmonary vascular resistance at 30 minutes after inhalation of study drug. Started Nov 2022; status: active, not recruiting.
02
Drugs
nitric oxide
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)Right heart dysfunction (RHF)
Beyond the preview
Go deeper on jRCT2051220042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220042.